Moti Ramgopal
 | This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (June 2025) |
Moti Navindra Ramgopal (born August 27, 1965) is a Guyanese American Infectious Disease physician[1] and clinical researcher who has contributed to research in HIV/AIDS, Hepatitis, COVID-19, and emerging infectious diseases.[2][3][4] He is the founder and medical Director of Midway Immunology and Research Center and founder and chairman of the Midway Specialty Care Center.[5][6][7] He also serves as a Clinical Professor of medicine at Florida State University (FSU), College of Medicine.[2][8]
Early life and education
[edit]After earning his Bachelor of Medicine, Bachelor of Surgery (MBBS) degree in 1989 at the University of the West Indies (UWI), Mona Campus in Kingston, Jamaica.[9]
Ramgopal left the Bahamas to complete his residency in internal medicine at Bon Se cours Hospital in Michigan, graduating in 1995. He then pursued a Fellowship in Infectious Diseases at Jackson Memorial Hospital and the University of Miami School of Medicine, completing it in 1997.[10]
Research
[edit]As a clinical researcher, Ramgopal has participated in numerous Phase II, III, and IV clinical trials, in HIV/AIDS, Hepatitis-C, Mycobacterial infections, COVID-19, Vaccines, and emerging infectious diseases (Mpox).[11] Ramgopal is published in peer-reviewed medical journals including The New England Journal of Medicine, The Lancet, Journal of the American Medical Association, and Clinical Infectious Diseases.[10][12]
In 2023, Ramgopal was the lead primary investigator of the SOLAR study, the first head-to-head clinical trial comparing the long-acting injectable HIV regimen cabotegravir/rilpivirine (CABENUVA) with the daily oral drug bictegravir/emtricitabine/tenofovir alafenamide (BIKTARVY). The study evaluated the efficacy, safety, and patient-reported outcomes of both treatments. Its findings contributed to the understanding of long-acting injectable HIV therapy as an alternative to daily oral antiretrovirals.[13][14]
References
[edit]- ^ "Home". Village Voice News. Retrieved 2025-06-23.
- ^ a b "Guyanese doctor leads clinical trial on 'antibody cocktail' given to President Trump". News Room Guyana. 2020-10-10. Retrieved 2025-06-23.
- ^ Washam, Cynthia. "Local bio-techs doing significant research on cure for HIV and AIDS". The Palm Beach Post. Retrieved 2025-06-23.
- ^ Rozier, Angela (2021-10-13). "'We have learned a huge horrible lesson': Palm Beach County doctor says COVID-19 trending in right direction". WPBF. Retrieved 2025-06-23.
- ^ Weber, Chuck (2020-03-10). "Local specialist talks coronavirus, being prepared in light of cancelled conference". WPEC. Retrieved 2025-06-23.
- ^ Weber, Chuck (2020-03-12). "Specialist warns of potential ventilator shortages". KFOX. Retrieved 2025-06-23.
- ^ Weber, Chuck (2020-06-09). "Treasure Coast doctors report spike in COVID hospitalizations". WPEC. Retrieved 2025-06-23.
- ^ "Long-acting injectable effective, well tolerated in patients with HIV regardless of race". www.healio.com. Retrieved 2025-06-23.
- ^ "usnews".
- ^ a b GTIMES (2020-10-18). "Dr Moti Ramgopal shares the journey of becoming a leading Infectious Diseases Specialist". Guyana Times. Retrieved 2025-06-23.
- ^ INEWS (2020-10-10). "US-based Guyanese doctor leads clinical trial on 'antibody cocktail' given to President Trump". INews Guyana. Retrieved 2025-06-23.
- ^ GTIMES (2020-10-10). "US-based Guyanese doctor leads clinical trial on "antibody cocktail" given to President Trump". Guyana Times. Retrieved 2025-06-23.
- ^ Ramgopal, Moti N.; Castagna, Antonella; Cazanave, Charles; Diaz-Brito, Vicens; Dretler, Robin; Oka, Shinichi; Osiyemi, Olayemi; Walmsley, Sharon; Sims, James; Di Perri, Giovanni; Sutton, Kenneth; Sutherland-Phillips, Denise; Berni, Alessandro; Latham, Christine L.; Zhang, Feifan. "Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial". The lancet. HIV. 10 (9): e566 – e577. doi:10.1016/S2352-3018(23)00136-4. ISSN 2352-3018. PMID 37567205.
- ^ Ramgopal, Moti N; Castagna, Antonella; Cazanave, Charles; Diaz-Brito, Vicens; Dretler, Robin; Oka, Shinichi; Osiyemi, Olayemi; Walmsley, Sharon; Sims, James; Di Perri, Giovanni; Sutton, Kenneth; Sutherland-Phillips, Denise; Berni, Alessandro; Latham, Christine L; Zhang, Feifan (2023-09-01). "Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial". The Lancet HIV. 10 (9): e566 – e577. doi:10.1016/S2352-3018(23)00136-4. ISSN 2352-3018.